In summary, well-selected MM patients may show rewarding response to daratumumab/CD38-antibody-retreatment, the more with different anti-myeloma combination drugs, initial good response and CD38-antibody treatment pauses, proving this retreatment as feasible, effective and non-toxic. The gene discussed is CD38; the disease is plasma cell myeloma.